{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:17:45Z","timestamp":1794464265880,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Gene Therapies, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s12325-023-02621-y","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T17:02:02Z","timestamp":1692205322000},"page":"4589-4605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5369-497X","authenticated-orcid":false,"given":"Walter","family":"Toro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Georgieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"LaMarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"2621_CR1","volume-title":"GeneReviews","author":"T Prior","year":"2022","unstructured":"Prior T, Leach M, Finanger E. Spinal muscular atrophy. In: Adam M, Everman D, Mirzaa G, editors. GeneReviews. Seattle: University of Washington; 2022."},{"issue":"1","key":"2621_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"2","key":"2621_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1750-3639.2001.tb00395.x","volume":"11","author":"H Schmalbruch","year":"2001","unstructured":"Schmalbruch H, Haase G. Spinal muscular atrophy: present state. Brain Pathol. 2001;11(2):231\u201347.","journal-title":"Brain Pathol"},{"issue":"4","key":"2621_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","volume":"14","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14(4):214\u201324.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"2621_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","volume":"21","author":"MA Waldrop","year":"2019","unstructured":"Waldrop MA, Kolb SJ. Current treatment options in neurology-SMA therapeutics. Curr Treat Options Neurol. 2019;21(6):25.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"2621_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/GIM.0b013e3182017c05","volume":"13","author":"S Ben-Shachar","year":"2011","unstructured":"Ben-Shachar S, Orr-Urtreger A, Bardugo E, et al. Large-scale population screening for spinal muscular atrophy: clinical implications. Genet Med. 2011;13(2):110\u20134.","journal-title":"Genet Med"},{"issue":"1","key":"2621_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, et al. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):1\u201310.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2621_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","volume":"62","author":"BT Darras","year":"2015","unstructured":"Darras BT. Spinal muscular atrophies. Pediatr Clin North Am. 2015;62(3):743\u201366.","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"2621_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1378\/chest.126.3.831","volume":"126","author":"C Ioos","year":"2004","unstructured":"Ioos C, Leclair-Richard D, Mrad S, et al. Respiratory capacity course in patients with infantile spinal muscular atrophy. Chest. 2004;126(3):831\u20137.","journal-title":"Chest"},{"key":"2621_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","volume":"15","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019;15:1153.","journal-title":"Ther Clin Risk Manag"},{"key":"2621_CR11","unstructured":"SPINRAZA. Highlights of prescribing information. Biogen; 2023 [updated 2023 February; cited 2023 March 31]. https:\/\/www.spinraza.com\/content\/dam\/commercial\/spinraza\/caregiver\/en_us\/pdf\/spinraza-prescribing-information.pdf."},{"key":"2621_CR12","unstructured":"ZOLGENSMA. Highlights of prescribing information. Novartis Gene Therapies, Inc.; 2023 [updated 2023 February; cited 2023 March 31]. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/zolgensma.pdf."},{"key":"2621_CR13","unstructured":"EVRYSDI. Highlights of prescribing information. Genentech, Inc.; 2023 [updated 2023 March; cited 2023 March 31]. https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf."},{"issue":"18","key":"2621_CR14","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"15","key":"2621_CR15","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317.","journal-title":"J Med Chem"},{"issue":"1","key":"2621_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"},{"issue":"18","key":"2621_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"7","key":"2621_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834\u201341.","journal-title":"JAMA Neurol"},{"issue":"4","key":"2621_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2621_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832\u201341.","journal-title":"Lancet Neurol"},{"issue":"8","key":"2621_CR21","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","volume":"19","author":"EP Armstrong","year":"2016","unstructured":"Armstrong EP, Malone DC, Yeh W-S, et al. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822\u20136.","journal-title":"J Med Econ"},{"issue":"1","key":"2621_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, et al. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70\u20139.","journal-title":"J Med Econ"},{"key":"2621_CR23","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","volume":"38","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, Cloutier M, Toro W, et al. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021;38:5809\u201328.","journal-title":"Adv Ther"},{"key":"2621_CR24","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1016\/j.jval.2018.04.1697","volume":"21","author":"O Dabbous","year":"2018","unstructured":"Dabbous O, Seda J, Sproule D. Economic burden of infant-onset (type 1) spinal muscular atrophy: a retrospective claims database analysis. Value Health. 2018;21:S251.","journal-title":"Value Health"},{"key":"2621_CR25","doi-asserted-by":"crossref","unstructured":"Goble J, Dai D, Boulos F, et al. The economic burden of spinal muscular atrophy patients in a commercially-insured population in the United States. Neurology. 2019;92(15_suppl):P1.6\u2013054.","DOI":"10.1212\/WNL.92.15_supplement.P1.6-054"},{"issue":"2","key":"2621_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijns7020026","volume":"7","author":"JE Hale","year":"2021","unstructured":"Hale JE, Darras BT, Swoboda KJ, et al. Massachusetts\u2019 findings from statewide newborn screening for spinal muscular atrophy. Int J Neonatal Screen. 2021;7(2):26.","journal-title":"Int J Neonatal Screen"},{"key":"#cr-split#-2621_CR27.1","unstructured":"Utah Department of Health & Human Services. All Utah newborns now tested for spinal muscular atrophy. [updated 2018 January 31"},{"key":"#cr-split#-2621_CR27.2","unstructured":"cited 2023 January 30]. https:\/\/health.utah.gov\/featured-news\/all-utah-newborns-now-tested-for-spinal-muscular-atrophy."},{"key":"#cr-split#-2621_CR28.1","unstructured":"NewSTEPs. Newborn screening status for all disorders [updated 2023 March 31"},{"key":"#cr-split#-2621_CR28.2","unstructured":"cited 2023 January 30]. https:\/\/www.newsteps.org\/resources\/data-visualizations\/newborn-screening-status-all-disorders?q=resources\/newborn-screening-status-all-disorders."},{"key":"2621_CR29","unstructured":"Merative. Micromedex (electronic version). [updated 2023; cited 2023 January 30]. https:\/\/www.micromedexsolutions.com."},{"key":"#cr-split#-2621_CR30.1","unstructured":"United States Bureau of Economic Analysis. Personal consumption expenditures price index. [updated 2023 March 31"},{"key":"#cr-split#-2621_CR30.2","unstructured":"cited 2022 December 6]. https:\/\/www.bea.gov\/data\/personal-consumption-expenditures-price-index."},{"issue":"3","key":"2621_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"28","key":"2621_CR32","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"4","key":"2621_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","volume":"54","author":"ST Normand","year":"2001","unstructured":"Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387\u201398.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2621_CR34","doi-asserted-by":"publisher","first-page":"1843277","DOI":"10.1080\/20016689.2020.1843277","volume":"8","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Kulas S, et al. Economic burden of spinal muscular atrophy: an analysis of claims data. J Mark Access Health Policy. 2020;8(1):1843277.","journal-title":"J Mark Access Health Policy"},{"key":"2621_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2018.11.002","volume":"92","author":"M Lee","year":"2019","unstructured":"Lee M, Fran\u00e7a UL, Graham RJ, et al. Pre-nusinersen hospitalization costs of children with spinal muscular atrophy. Pediatr Neurol. 2019;92:3\u20135.","journal-title":"Pediatr Neurol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02621-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T04:39:51Z","timestamp":1702960791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02621-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2621"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02621-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"31 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}